These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31988134)

  • 21. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
    Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
    Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategic Variants of CSP Delivered as SynDNA Vaccines Demonstrate Heterogeneity of Immunogenicity and Protection from
    Reeder SM; Bah MA; Tursi NJ; Brooks RC; Patel A; Esquivel R; Eaton A; Jhun H; Chu J; Kim K; Xu Z; Zavala F; Weiner DB
    Infect Immun; 2021 Sep; 89(10):e0072820. PubMed ID: 34152830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.
    Porter MD; Nicki J; Pool CD; DeBot M; Illam RM; Brando C; Bozick B; De La Vega P; Angra D; Spaccapelo R; Crisanti A; Murphy JR; Bennett JW; Schwenk RJ; Ockenhouse CF; Dutta S
    Clin Vaccine Immunol; 2013 Jun; 20(6):803-10. PubMed ID: 23536694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.
    Ajua A; Lell B; Agnandji ST; Asante KP; Owusu-Agyei S; Mwangoka G; Mpina M; Salim N; Tanner M; Abdulla S; Vekemans J; Jongert E; Lievens M; Cambron P; Ockenhouse CF; Kremsner PG; Mordmüller B
    Malar J; 2015 Feb; 14():72. PubMed ID: 25885325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
    White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
    Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.
    Zeeshan M; Alam MT; Vinayak S; Bora H; Tyagi RK; Alam MS; Choudhary V; Mittra P; Lumb V; Bharti PK; Udhayakumar V; Singh N; Jain V; Singh PP; Sharma YD
    PLoS One; 2012; 7(8):e43430. PubMed ID: 22912873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy.
    Dobaño C; Sanz H; Sorgho H; Dosoo D; Mpina M; Ubillos I; Aguilar R; Ford T; Díez-Padrisa N; Williams NA; Ayestaran A; Traore O; Nhabomba AJ; Jairoce C; Waitumbi J; Agnandji ST; Kariuki S; Abdulla S; Aponte JJ; Mordmüller B; Asante KP; Owusu-Agyei S; Tinto H; Campo JJ; Moncunill G; Gyan B; Valim C; Daubenberger C
    Nat Commun; 2019 May; 10(1):2174. PubMed ID: 31092823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Production and molecular characterization of Plasmodium falciparum recombinant circumsporozoite protein with 37 NANP and 4 NVDP epitopes].
    Uyar Y; Akşit A; Karaca S; Ceylan ŞS; Yürük M
    Mikrobiyol Bul; 2017 Jan; 51(1):41-51. PubMed ID: 28283009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs.
    Murugan R; Scally SW; Costa G; Mustafa G; Thai E; Decker T; Bosch A; Prieto K; Levashina EA; Julien JP; Wardemann H
    Nat Med; 2020 Jul; 26(7):1135-1145. PubMed ID: 32451496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.
    Wang LT; Pereira LS; Kiyuka PK; Schön A; Kisalu NK; Vistein R; Dillon M; Bonilla BG; Molina-Cruz A; Barillas-Mury C; Tan J; Idris AH; Francica JR; Seder RA
    PLoS Pathog; 2021 Dec; 17(12):e1010133. PubMed ID: 34871332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.
    Birkett A; Lyons K; Schmidt A; Boyd D; Oliveira GA; Siddique A; Nussenzweig R; Calvo-Calle JM; Nardin E
    Infect Immun; 2002 Dec; 70(12):6860-70. PubMed ID: 12438363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.
    Collins KA; Snaith R; Cottingham MG; Gilbert SC; Hill AVS
    Sci Rep; 2017 Apr; 7():46621. PubMed ID: 28422178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies.
    Espinosa DA; Gutierrez GM; Rojas-López M; Noe AR; Shi L; Tse SW; Sinnis P; Zavala F
    J Infect Dis; 2015 Oct; 212(7):1111-9. PubMed ID: 25762791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.
    Ubillos I; Ayestaran A; Nhabomba AJ; Dosoo D; Vidal M; Jiménez A; Jairoce C; Sanz H; Aguilar R; Williams NA; Díez-Padrisa N; Mpina M; Sorgho H; Agnandji ST; Kariuki S; Mordmüller B; Daubenberger C; Asante KP; Owusu-Agyei S; Sacarlal J; Aide P; Aponte JJ; Dutta S; Gyan B; Campo JJ; Valim C; Moncunill G; Dobaño C
    BMC Med; 2018 Oct; 16(1):197. PubMed ID: 30376866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum.
    Clement F; Dewar V; Van Braeckel E; Desombere I; Dewerchin M; Swysen C; Demoitié MA; Jongert E; Cohen J; Leroux-Roels G; Cambron P
    Malar J; 2012 Nov; 11():384. PubMed ID: 23173602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein.
    Speake C; Pichugin A; Sahu T; Malkov V; Morrison R; Pei Y; Juompan L; Milman N; Zarling S; Anderson C; Wong-Madden S; Wendler J; Ishizuka A; MacMillen ZW; Garcia V; Kappe SH; Krzych U; Duffy PE
    PLoS One; 2016; 11(7):e0159449. PubMed ID: 27434123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
    Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
    Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity.
    Thai E; Costa G; Weyrich A; Murugan R; Oyen D; Flores-Garcia Y; Prieto K; Bosch A; Valleriani A; Wu NC; Pholcharee T; Scally SW; Wilson IA; Wardemann H; Julien JP; Levashina EA
    J Exp Med; 2020 Nov; 217(11):. PubMed ID: 32790871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.